Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
VRTX Revenue Growth (YoY Quarterly)•+10.82%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+10.82%
-0.2pp
+10.95%
-0.9pp
+14.28%
+8.7pp
+26.74%
+20.5pp
+30.46%
+26.9pp
+32.11%
+27.4pp
+32.86%
+28.1pp
-1.40%
-0.5pp
-1.69%
-0.4pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +15.66% | +3.09% | +12.06% | +10.99% | +10.82% |
| Gross Profit Growth | +15.76% | +2.67% | +12.47% | +11.86% | +10.95% |
| EBITDA Growth | -2.69% | -41.79% | +0.00% | +5.55% | +14.28% |
| Operating Income Growth | +3.79% | -44.70% | +0.00% | +6.26% | +26.74% |
| Net Income Growth | -5.76% | -41.22% | +0.00% | +3.59% | +30.46% |
| EPS Growth | -5.59% | -40.85% | +0.00% | +4.69% | +32.11% |
| EPS Diluted Growth | -5.66% | -40.86% | +0.00% | +4.74% | +32.86% |
| Weighted Average Shares Growth | -0.08% | -0.50% | -0.54% | -0.93% | -1.40% |
| Weighted Average Shares Diluted Growth | -0.15% | -0.61% | +0.31% | -1.30% | -1.69% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +149.19% | -37.33% | +0.00% | -9.37% | -14.81% |
| Free Cash Flow Growth | +178.75% | -26.46% | +0.00% | -12.48% | -29.15% |
| Receivables Growth | +2.94% | +0.66% | +14.33% | +11.18% | +27.55% |
| Inventory Growth | +63.16% | +67.22% | +63.93% | +50.66% | +39.94% |
| Asset Growth | -0.87% | -4.34% | +19.39% | +11.79% | +16.02% |
| Book Value per Share Growth | -6.59% | -10.60% | +16.88% | +11.84% | +15.36% |
| Debt Growth | +116.42% | +128.63% | +63.64% | +7.75% | +121.92% |
| R&D Expense Growth | -26.12% | +13.14% | -81.93% | +17.84% | -2.50% |
| SG&A Expenses Growth | +2.30% | +15.67% | +14.08% | +19.71% | +28.97% |
1 / 4